Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months

  • Marcella Rodrigues Guedes
  • Ricardo José Fittipaldi-FernandezEmail author
  • Cristina Fajardo Diestel
  • Márcia Regina Simas Torres Klein
Original Contributions



Obesity is an important risk factor for several chronic diseases and also is associated with worse quality of life. Intragastric balloon (IGB) is an effective method for weight loss. Although changes in lifestyle are critical to weight loss during and after IGB therapy, only a few studies evaluated dietary intake and none evaluated changes in physical activity with a validated questionnaire during the treatment. The aim of this study was to evaluate changes in total and central body adiposity, dietary intake, physical activity, and quality of life of patients with obesity submitted to IGB treatment for 6 months.


Prospective observational study involving 42 patients with obesity using IGB for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB for total and central body adiposity (anthropometry and bioelectrical impedance), dietary intake, physical activity (Baecke questionnaire), and quality of life (SF-36 questionnaire).


There was a significant decrease in total and central body adiposity. The mean % total weight loss and % excess weight loss were 15.88 ± 1.42 and 56.04 ± 4.90, respectively and waist circumference decreased 13.33 ± 1.39 cm. There was a reduction in energy intake, an increase in physical activity, and an improvement of quality of life during IGB treatment.


The present study suggests that IGB treatment during 6 months in individuals with obesity is effective for decreasing total and central body adiposity being associated with reduction in energy intake, increase in physical activity, and improvement in quality of life.


Intragastric balloon Obesity Weight loss Quality of life Dietary intake 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Human Rights

The study was reviewed and approved by the Committee on Ethics and Research of Pedro Ernesto University Hospital/Rio de Janeiro State University.

All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Ng M, Fleming T, Robinson M, et al. Global, regional and national prevalence on overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017 377(1):13–27.Google Scholar
  3. 3.
    Jensen MD, Ryan DH, Apovian CM, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.CrossRefPubMedGoogle Scholar
  4. 4.
    Bray GA, Kim KK, JPH W. World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Meldrum DR, Morris MA, Gambone JC. Obesity pandemic: causes, consequences, and solutions-but do we have the will? Fertil Steril. 2017;107(4):833–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kahan S, Zvenyach T. Obesity as a disease: current policies and implications for the future. Curr Obes Rep. 2016;5(2):291–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Upadhyay J, Farr O, Perakakis N, et al. Obesity as a disease. Med Clin N Am. 2018;(102):13–33.Google Scholar
  8. 8.
    Pan A, Kawachi I, Luo N, et al. Changes in body weight and health-related quality of life: 2 cohorts of us women. Am J Epidemiol. 2014;180(3):254–62.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pimenta FB, Bertrand E, Mograbi DC, et al. The relationship between obesity and quality of life in Brazilian adults. Front Psychol. 2015;6:966.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    WHO - World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Techinical Report Series (894).Geneva, 2000.Google Scholar
  11. 11.
    Després JP. Waist circumference as a vital sign in cardiology 20 years after initial publication in the American Journal of Cardiology. Am J Cardiol. 2014;114(2):320–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Garvey WT, Mechanick JI, Brett EM, et al. American Association Of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity executive Summary Complete Guidelines available at Endocr Pract. 2016;22(7):842–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. Diretrizes brasileiras de obesidade 2016 / ABESO - Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. – 4.ed. - São Paulo, SP. Disponível em:
  14. 14.
    Wadden TA, Webb VL, Moran CH, et al. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation. 2012;125(9):1157–70.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yumuk V, Tsigos C, Fried M, et al. Obesity management task force of the european association for the study of obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402–24.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ali MR, Moustarah F, Kim JJ. American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis. 2016;12(3):462–7.CrossRefGoogle Scholar
  17. 17.
    Laing P, Pham T, Taylor LJ, et al. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci. 2017;62(6):1399–408.CrossRefGoogle Scholar
  18. 18.
    Neto MG, Silva LB, Grecco E, de Quadros LG, Teixeira A, Souza T et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2017;28. pii: S1550–S7289.
  19. 19.
    Kim SH, Chun HJ, Choi HS, et al. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016;22(24):5495–504.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematic review. Obes Surg. 2016;26(9):2248–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Donadio F, Sburlati LF, Masserini B, et al. Metabolic parameters after BioEnterics Intragastric Balloon placement in obese patients. J Endocrinol Investig. 2009;32(2):165–8.CrossRefGoogle Scholar
  22. 22.
    Karagiozoglou-Lampoudi T, Papakostas P, Penna S, et al. Effective intragastric balloon treatment in obese adolescents. Ann Gastroenterol. 2009;22(1):46–51.Google Scholar
  23. 23.
    Mui WL, Ng EK, Tsung BY, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20:1128–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Fuller NR, Lau NS, Denyer G, et al. An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY. Clin Obes. 2013;3(6):172–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Genco A, Maselli R, Cipriano M, et al. Long-term multiple intragastric balloon treatment—a new strategy to treat morbid obese patients refusing surgery: prospective 6-year follow-up study. Surg Obes Relat Dis. 2014;10(2):307–11.CrossRefGoogle Scholar
  26. 26.
    Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes. 2017;41(3):427–33.CrossRefGoogle Scholar
  27. 27.
    Guedes EP, Madeira E, Mafort TT, et al. Impact of 6 months of treatment with intragastric balloon on body fat and quality of life in obese individuals with metabolic syndrome. Health Qual Life Outcomes. 2017;15:211.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Reimão SM, da Silva MER, Nunes GC, et al. Improvement of body composition and quality of life following intragastric balloon. Obes Surg. 2018;28(6):1806–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Kyle UG, Bosaeus I, Lorenzo ADD, et al. Bioelectrical impedance analysis part I: review of principles and methods. ESPEN Guidelines Clin Nutr. 2004;23:1226–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Fittipaldi-Fernandez RJ, Guedes MR, Galvao Neto MP, et al. Efficacy of intragastric balloon treatment for adolescent obesity. Obes Surg. 2017;27(10):2546–51.CrossRefPubMedGoogle Scholar
  31. 31.
    Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013;23(12):2068–74.CrossRefPubMedGoogle Scholar
  32. 32.
    Mitura K, Garnysz K. Tolerance of intragastric balloon and patient’s satisfaction in obesity treatment. Wideochir Inne Tech Maloinwazyjne. 2015;10(3):445–9.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Genco A, Ienca R, Ernesti I, et al. Improving weight loss by combination of two temporary antiobesity treatments. Obes Surg. 2018;28:3733–7. Scholar
  34. 34.
    Ribeiro da Silva J, Proença L, Rodrigues A, et al. Intragastric balloon for obesity treatment: safety, tolerance, and efficacy. GE Port J Gastroenterol. 2018;25(5):236–42.CrossRefPubMedGoogle Scholar
  35. 35.
    WHO STEP wise approach to surveillance (STEPS). [homepage na Internet] Geneva: World Health Organization (WHO), 2008. available at:
  36. 36.
    Bergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. Obesity (Silver Spring). 2011;19(5):1083–9.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Zhou JY, Ge H, Zhu M, et al. Neck circumference as an independent predictive contributor to cardio-metabolic syndrome. Cardiovasc Diabetol. 2013;12(76):2–7.Google Scholar
  38. 38.
    Segal KR, Van Loan M, Fitzgerald PI, et al. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-Validation study. Am J Clin Nutr. l988;47:7–14.Google Scholar
  39. 39.
    Gray DS, Bray GA, Gemayel N, et al. Effect of obesity on bioelectrical impedance. Am J Clin Nutr. l989;50:–255, 60.Google Scholar
  40. 40.
    Sichieri R, Everhart JE. Validity of a brazilian food frequency questionnaire against dietary recalls and estimated energy intake. Nutr Res. 1998;18(10):1649–59.CrossRefGoogle Scholar
  41. 41.
    Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36(5):936–42.CrossRefPubMedGoogle Scholar
  42. 42.
    Florindo AA, Latorre MRDO. Validação e reprodutibilidade do questionário de Baecke de avaliação da atividade física habitual em homens adultos. Rev Bras Med Esporte. 2003;9(3):121–8.CrossRefGoogle Scholar
  43. 43.
    Ciconelli RM, Ferraz MB, Santos W, et al. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol. 1999;39(3):143–50.Google Scholar
  44. 44.
    Al-Sabah S, Al-Ghareeb F, Ali DA, et al. Efficacy of intragastric balloon for the management of obesity: experience from Kuwait. Surg Endosc. 2016;30(2):424–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12(2):420–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Nunes GC, Pajecki D, de Melo ME, et al. Assessment of weight loss with the intragastric balloon in patients with different degrees of obesity. Surg Laparosc Endosc Percutan Tech. 2017;27(4):e83–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Mafort TT, Madeira E, Madeira M, et al. Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome. Obes Surg. 2014;24(2):232–40.CrossRefPubMedGoogle Scholar
  48. 48.
    Zheng Y, Wang M, He S, et al. Short-term effects of intragastric balloon in association with conservative therapy on weight loss: a meta-analysis. J Transl Med. 2015;13:246.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hall K, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin N Am. 2018;102:183–97.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Gastroenterology Endogastro Rio ClinicRio de JaneiroBrazil
  2. 2.Post Graduation Program in Clinical and Experimental PathophysiologyRio de Janeiro State UniversityRio de JaneiroBrazil
  3. 3.Department of Applied Nutrition, Nutrition InstituteRio de Janeiro State UniversityRio de JaneiroBrazil

Personalised recommendations